GLP-1 RA - Follow-up Survey | the Endocrine Society Center for Learning

Dear attendee, please complete this follow-up survey to help us measure the impact of our program on your practice.

Compared to before participating in this CME activity, how often do you now implement each of the following strategies when managing the care of patients with type 2 diabetes mellitus? *

	Much more often	More often	About the same	Less often	Much less often	N/A
Utilize short-acting GLP-1 RAs for appropriate patients	Utilize short-acting GLP-1 RAs for appropriate patients - Much more often	Utilize short-acting GLP-1 RAs for appropriate patients - More often	Utilize short-acting GLP-1 RAs for appropriate patients - About the same	Utilize short-acting GLP-1 RAs for appropriate patients - Less often	Utilize short-acting GLP-1 RAs for appropriate patients - Much less often	Utilize short-acting GLP-1 RAs for appropriate patients - N/A
Utilize long-acting GLP-1 RAs for appropriate patients	Utilize long-acting GLP-1 RAs for appropriate patients - Much more often	Utilize long-acting GLP-1 RAs for appropriate patients - More often	Utilize long-acting GLP-1 RAs for appropriate patients - About the same	Utilize long-acting GLP-1 RAs for appropriate patients - Less often	Utilize long-acting GLP-1 RAs for appropriate patients - Much less often	Utilize long-acting GLP-1 RAs for appropriate patients - N/A
Utilize both short-and long-acting GLP-1 RAs more frequently	Utilize both short-and long-acting GLP-1 RAs more frequently - Much more often	Utilize both short-and long-acting GLP-1 RAs more frequently - More often	Utilize both short-and long-acting GLP-1 RAs more frequently - About the same	Utilize both short-and long-acting GLP-1 RAs more frequently - Less often	Utilize both short-and long-acting GLP-1 RAs more frequently - Much less often	Utilize both short-and long-acting GLP-1 RAs more frequently - N/A
Consider GLP-1 RAs in patients with a history of pancreatitis	Consider GLP-1 RAs in patients with a history of pancreatitis - Much more often	Consider GLP-1 RAs in patients with a history of pancreatitis - More often	Consider GLP-1 RAs in patients with a history of pancreatitis - About the same	Consider GLP-1 RAs in patients with a history of pancreatitis - Less often	Consider GLP-1 RAs in patients with a history of pancreatitis - Much less often	Consider GLP-1 RAs in patients with a history of pancreatitis - N/A
Use a GLP-1 RA instead of basal insulin for patients who have an inadequate response to oral antidiabetic	Use a GLP-1 RA instead of basal insulin for patients who have an inadequate response to oral antidiabetic - Much more often	Use a GLP-1 RA instead of basal insulin for patients who have an inadequate response to oral antidiabetic - More often	Use a GLP-1 RA instead of basal insulin for patients who have an inadequate response to oral antidiabetic - About the same	Use a GLP-1 RA instead of basal insulin for patients who have an inadequate response to oral antidiabetic - Less often	Use a GLP-1 RA instead of basal insulin for patients who have an inadequate response to oral antidiabetic - Much less often	Use a GLP-1 RA instead of basal insulin for patients who have an inadequate response to oral antidiabetic - N/A
Use basal insulin in combination with a GLP-1 RA for patients with T2DM	Use basal insulin in combination with a GLP-1 RA for patients with T2DM - Much more often	Use basal insulin in combination with a GLP-1 RA for patients with T2DM - More often	Use basal insulin in combination with a GLP-1 RA for patients with T2DM - About the same	Use basal insulin in combination with a GLP-1 RA for patients with T2DM - Less often	Use basal insulin in combination with a GLP-1 RA for patients with T2DM - Much less often	Use basal insulin in combination with a GLP-1 RA for patients with T2DM - N/A

Compared to your confidence before participating in this CME activity, how confident are you now in performing each of the following tasks? *

	Much more confident	More confident	About the same	Less confident	Much less confident
Evaluating the most recent evidence when considering use of GLP-1 RA as part of T2DM treatment plan	Evaluating the most recent evidence when considering use of GLP-1 RA as part of T2DM treatment plan - Much more confident	Evaluating the most recent evidence when considering use of GLP-1 RA as part of T2DM treatment plan - More confident	Evaluating the most recent evidence when considering use of GLP-1 RA as part of T2DM treatment plan - About the same	Evaluating the most recent evidence when considering use of GLP-1 RA as part of T2DM treatment plan - Less confident	Evaluating the most recent evidence when considering use of GLP-1 RA as part of T2DM treatment plan - Much less confident
Applying updated safety data for the GLP-1 RA drug class	Applying updated safety data for the GLP-1 RA drug class - Much more confident	Applying updated safety data for the GLP-1 RA drug class - More confident	Applying updated safety data for the GLP-1 RA drug class - About the same	Applying updated safety data for the GLP-1 RA drug class - Less confident	Applying updated safety data for the GLP-1 RA drug class - Much less confident
Discussing the nonglycemic effects of GLP-1 RAs, including their positive impact on weight and cardiovascular risk factors	Discussing the nonglycemic effects of GLP-1 RAs, including their positive impact on weight and cardiovascular risk factors - Much more confident	Discussing the nonglycemic effects of GLP-1 RAs, including their positive impact on weight and cardiovascular risk factors - More confident	Discussing the nonglycemic effects of GLP-1 RAs, including their positive impact on weight and cardiovascular risk factors - About the same	Discussing the nonglycemic effects of GLP-1 RAs, including their positive impact on weight and cardiovascular risk factors - Less confident	Discussing the nonglycemic effects of GLP-1 RAs, including their positive impact on weight and cardiovascular risk factors - Much less confident
Utilizing GLP-1 RAs more effectively in appropriate patients with T2DM	Utilizing GLP-1 RAs more effectively in appropriate patients with T2DM - Much more confident	Utilizing GLP-1 RAs more effectively in appropriate patients with T2DM - More confident	Utilizing GLP-1 RAs more effectively in appropriate patients with T2DM - About the same	Utilizing GLP-1 RAs more effectively in appropriate patients with T2DM - Less confident	Utilizing GLP-1 RAs more effectively in appropriate patients with T2DM - Much less confident

As a result of implementing these practice changes, what significant patient outcomes have you observed?

Which of the following barriers or challenges did you encounter in implementing these changes? Select all that apply: *

Cost/reimbursement

Time management

Patient adherence

Limitations of support staff (training, availability, etc)

Cost-effectiveness

Formulary

No barriers or challenges encountered

Other...

Which of the following barriers or challenges did you encounter in implementing these changes? Select all that apply: Other...

How many patients with T2DM do you see in your practice in a typical week? *

In your estimation, how many patients have benefited from your participation in this activity? *

10% or fewer

As many as 25%

As many as 50%

The majority of my patients with endometriosis/pelvic pain

N/A, I don't treat such patients

Please share any additional feedback you have about the program.

Leave this field blank

the Endocrine Society Center for Learning

Hormone Science to Health

Applying the Evidence for GLP-1 Receptor Agonists in Type 2 Diabetes: Practice Perspectives

GLP-1 RA - Follow-up Survey

Dear attendee, please complete this follow-up survey to help us measure the impact of our program on your practice.

Clinical Pearls

Evaluation

Claim Credit

Follow-up Survey

Course navigation

You are here

Applying the Evidence for GLP-1 Receptor Agonists in Type 2 Diabetes: Practice Perspectives

GLP-1 RA - Follow-up Survey

Dear attendee, please complete this follow-up survey to help us measure the impact of our program on your practice.

Clinical Pearls

Evaluation

Claim Credit

Follow-up Survey

Course navigation